| Width: | 300px |
| Class: | Erythropoietin receptor agonist |
| Cas Number: | 1208243-50-8 |
| Pubchem: | 91810664 |
| Drugbank: | DB13006 |
| Chemspiderid: | 35013013 |
| Unii: | 9W5677JKDA |
| Kegg: | D11218 |
| Chembl: | 3545305 |
| Synonyms: | ARA-290; ARA290; PHBSP; pHBSP peptide; pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser; Pyroglutamate helix B surface peptide; UEQLERALNSS |
| Iupac Name: | (4S)-5-(2S)-5-amino-1-(2S)-1-(2S)-1-(2S)-1-(2S)-1-(2S)-1-(2S)-4-amino-1-(2S)-1-(1S)-1-carboxy-2-hydroxyethylamino]-3-hydroxy-1-oxopropan-2-ylamino]-1,4-dioxobutan-2-ylamino]-4-methyl-1-oxopentan-2-ylamino]-1-oxopropan-2-ylamino]-5-(diaminomethylideneamino)-1-oxopentan-2-ylamino]-4-carboxy-1-oxobutan-2-ylamino]-4-methyl-1-oxopentan-2-ylamino]-1,5-dioxopentan-2-ylamino]-5-oxo-4-(2S)-5-oxopyrrolidine-2-carbonylamino]pentanoic acid| C=51 | H=84 | N=16 | O=21| SMILES = C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]1CCC(=O)N1| StdInChI = 1S/C51H84N16O21/c1-22(2)17-30(47(84)65-32(19-36(53)71)48(85)66-33(20-68)49(86)67-34(21-69)50(87)88)63-40(77)24(5)57-41(78)25(7-6-16-56-51(54)55)59-43(80)29(11-15-39(75)76)62-46(83)31(18-23(3)4)64-45(82)27(8-12-35(52)70)60-44(81)28(10-14-38(73)74)61-42(79)26-9-13-37(72)58-26/h22-34,68-69H,6-21H2,1-5H3,(H2,52,70)(H2,53,71)(H,57,78)(H,58,72)(H,59,80)(H,60,81)(H,61,79)(H,62,83)(H,63,77)(H,64,82)(H,65,84)(H,66,85)(H,67,86)(H,73,74)(H,75,76)(H,87,88)(H4,54,55,56)/t24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-/m0/s1| StdInChIKey = WZTIQQBMSJTRBR-WYKNNRPVSA-N}} Cibinetide (; ; developmental code name ARA-290) is an erythropoietin receptor agonist which is under development for the treatment of a variety of different medical conditions.[1] [2] [3] It was also under development for the treatment of depressive disorders, but development for this indication was discontinued. The drug is under development by Araim Pharmaceuticals. References |